Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Novo Nordisk A/S

Clinicaltrial registered12 Nov 2026

Novo Nordisk A/S

12 Nov 2026: Trial registered · A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
12 Nov 2026
Title
A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
Conditions
Diabetes Mellitus, Type 2
Phase
Phase 3
Study Type
Interventional
Status
Not Yet Recruiting
Countries
United States, Argentina, Brazil, Bulgaria, China, Croatia, Hungary, Japan, Poland, Portugal, Saudi Arabia, Serbia, South Korea, Spain, Taiwan, United Kingdom
Country
United States
Reference
NCT07931599
Location
United States, Argentina, Brazil
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Novo Nordisk A/S

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Novo Nordisk A/S in our registers.

More from United States

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.